[HTML][HTML] Upper tract urothelial carcinoma: a different disease entity in terms of management
JJ Leow, KT Chong, SL Chang, J Bellmunt - ESMO open, 2016 - Elsevier
Upper tract urothelial carcinomas (UTUCs) consist of 5%–10% of all urothelial carcinomas,
the rest being urothelial carcinomas of the bladder (UCB). There is increasing evidence to …
the rest being urothelial carcinomas of the bladder (UCB). There is increasing evidence to …
[HTML][HTML] The role of transurethral resection in trimodal therapy for muscle-invasive bladder cancer
CM Russell, AH Lebastchi, T Borza, DE Spratt… - Bladder …, 2016 - content.iospress.com
While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the
accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment …
accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment …
[HTML][HTML] Perioperative treatment and radical cystectomy for bladder cancer–a population based trend analysis of 10,338 patients in the Netherlands
TJN Hermans, EEF van de Putte, S Horenblas… - European Journal of …, 2016 - Elsevier
Abstract Background In Europe, population-based data concerning perioperative treatment
(PT) and radical cystectomy (RC) are lacking. We assessed temporal trends in PT …
(PT) and radical cystectomy (RC) are lacking. We assessed temporal trends in PT …
[HTML][HTML] Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer
TL Rose, AM Deal, S Ladoire, G Créhange… - Bladder …, 2016 - content.iospress.com
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder
cancer (MIBC) includes a maximal transurethral resection followed by concurrent …
cancer (MIBC) includes a maximal transurethral resection followed by concurrent …
Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises
JB Aragon-Ching, DL Trump - Future Oncology, 2016 - Taylor & Francis
Bladder urothelial cancers remain an important urologic cancer with limited treatment
options in the locally advanced and metastatic setting. While neoadjuvant chemotherapy for …
options in the locally advanced and metastatic setting. While neoadjuvant chemotherapy for …
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope
R Morales-Barrera, C Suárez, AM de Castro… - Cancer Treatment …, 2016 - Elsevier
Bladder cancer is one of the leading causes of death in Europe and the United States. About
25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic …
25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic …
ASCO endorses EAU muscle-invasive bladder cancer guidelines
SP Lerner - Nature Reviews Urology, 2016 - nature.com
A multidisciplinary expert panel from the American Society of Clinical Oncology has
endorsed the updated European Association of Urology guidelines for the management of …
endorsed the updated European Association of Urology guidelines for the management of …
[HTML][HTML] Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based …
N Houede, G Locker, C Lucas, HS Parra, U Basso… - BMC cancer, 2016 - Springer
Background Platinum-based systemic chemotherapy is considered the backbone for
management of advanced urothelial carcinomas. However there is a lack of real world data …
management of advanced urothelial carcinomas. However there is a lack of real world data …